Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 29.1
(-3.64%)
SEK 29.1
(-3.64%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 42.3 Million SEK | -81.43% |
| 2022 | 227.78 Million SEK | -4.42% |
| 2021 | 238.3 Million SEK | -6.28% |
| 2020 | 254.27 Million SEK | 254.35% |
| 2019 | 71.76 Million SEK | -49.37% |
| 2018 | 141.74 Million SEK | -8.54% |
| 2017 | 154.97 Million SEK | 209.95% |
| 2016 | 50 Million SEK | 0.0% |
| 2015 | - SEK | -100.0% |
| 2014 | 195.56 Million SEK | -54.25% |
| 2013 | 427.5 Million SEK | -7.32% |
| 2012 | 461.25 Million SEK | 5.21% |
| 2011 | 438.4 Million SEK | 187.94% |
| 2010 | 152.25 Million SEK | -33.74% |
| 2009 | 229.79 Million SEK | -26.64% |
| 2008 | 313.22 Million SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 170.94 Million SEK | 0.0% |
| 2024 Q3 | - SEK | 0.0% |
| 2024 Q2 | 48.03 Million SEK | -100.0% |
| 2023 Q3 | 224.02 Million SEK | -1.27% |
| 2023 FY | 42.3 Million SEK | -81.43% |
| 2023 Q1 | 229.84 Million SEK | 0.91% |
| 2023 Q2 | 226.89 Million SEK | -1.29% |
| 2023 Q4 | 42.3 Million SEK | -81.12% |
| 2022 Q3 | 230.71 Million SEK | -0.76% |
| 2022 FY | 227.78 Million SEK | -4.42% |
| 2022 Q1 | 234.9 Million SEK | -1.43% |
| 2022 Q4 | 227.78 Million SEK | -1.27% |
| 2022 Q2 | 232.48 Million SEK | -1.03% |
| 2021 Q2 | 255.58 Million SEK | -0.94% |
| 2021 Q3 | 239.23 Million SEK | -6.39% |
| 2021 Q4 | 238.3 Million SEK | -0.39% |
| 2021 FY | 238.3 Million SEK | -6.28% |
| 2021 Q1 | 258 Million SEK | 1.47% |
| 2020 Q2 | 248.21 Million SEK | -1.17% |
| 2020 Q1 | 251.14 Million SEK | 249.98% |
| 2020 Q3 | 259.46 Million SEK | 4.53% |
| 2020 Q4 | 254.27 Million SEK | -2.0% |
| 2020 FY | 254.27 Million SEK | 254.35% |
| 2019 Q2 | 212.34 Million SEK | -2.78% |
| 2019 Q1 | 218.41 Million SEK | 54.09% |
| 2019 Q3 | 195.19 Million SEK | -8.08% |
| 2019 Q4 | 71.76 Million SEK | -63.24% |
| 2019 FY | 71.76 Million SEK | -49.37% |
| 2018 Q3 | 146.33 Million SEK | -1.1% |
| 2018 Q2 | 147.95 Million SEK | -9.24% |
| 2018 Q1 | 163.01 Million SEK | 5.19% |
| 2018 FY | 141.74 Million SEK | -8.54% |
| 2018 Q4 | 141.74 Million SEK | -3.13% |
| 2017 Q4 | 154.97 Million SEK | 1106.13% |
| 2017 Q2 | 13.9 Million SEK | -78.24% |
| 2017 Q1 | 63.92 Million SEK | 27.85% |
| 2017 FY | 154.97 Million SEK | 209.95% |
| 2017 Q3 | 12.84 Million SEK | -7.61% |
| 2016 FY | 50 Million SEK | 0.0% |
| 2016 Q4 | 50 Million SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | -100.0% |
| 2015 Q4 | - SEK | -100.0% |
| 2015 Q3 | 140.39 Million SEK | -18.61% |
| 2015 Q2 | 172.49 Million SEK | -6.0% |
| 2015 Q1 | 183.5 Million SEK | -6.17% |
| 2014 Q1 | 436.5 Million SEK | 2.11% |
| 2014 FY | 195.56 Million SEK | -54.25% |
| 2014 Q4 | 195.56 Million SEK | -9.59% |
| 2014 Q3 | 216.31 Million SEK | -5.62% |
| 2014 Q2 | 229.2 Million SEK | -47.49% |
| 2013 Q3 | 441 Million SEK | -2.0% |
| 2013 Q4 | 427.5 Million SEK | -3.06% |
| 2013 FY | 427.5 Million SEK | -7.32% |
| 2013 Q1 | 450 Million SEK | -2.44% |
| 2013 Q2 | 450 Million SEK | 0.0% |
| 2012 Q3 | 457.59 Million SEK | -0.51% |
| 2012 Q2 | 459.94 Million SEK | 0.0% |
| 2012 FY | 461.25 Million SEK | 5.21% |
| 2012 Q4 | 461.25 Million SEK | 0.8% |
| 2011 Q4 | 438.4 Million SEK | 0.0% |
| 2011 FY | 438.4 Million SEK | 187.94% |
| 2010 FY | 152.25 Million SEK | -33.74% |
| 2009 FY | 229.79 Million SEK | -26.64% |
| 2008 FY | 313.22 Million SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 97.096% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 97.096% |
| Arcoma AB | 1.92 Million SEK | -2095.433% |
| BICO Group AB (publ) | 1.75 Billion SEK | 97.59% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 26.679% |
| CellaVision AB (publ) | 28.66 Million SEK | -47.593% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -18871.3% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | -2313.349% |
| Duearity AB (publ) | 2.94 Million SEK | -1338.98% |
| Dignitana AB (publ) | 6.07 Million SEK | -596.166% |
| Episurf Medical AB (publ) | 2.3 Million SEK | -1739.391% |
| Getinge AB (publ) | 3.9 Billion SEK | 98.916% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | -565.93% |
| Iconovo AB (publ) | 4.9 Million SEK | -762.174% |
| Integrum AB (publ) | 4.84 Million SEK | -773.27% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -20434.501% |
| Mentice AB (publ) | 2.14 Million SEK | -1873.228% |
| OssDsign AB (publ) | 214 Thousand SEK | -19669.159% |
| Paxman AB (publ) | 2.53 Million SEK | -1570.853% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | -1308.322% |
| SciBase Holding AB (publ) | 4.17 Million SEK | -912.347% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | -120.298% |
| Sedana Medical AB (publ) | 1.01 Million SEK | -4080.435% |
| Senzime AB (publ) | 8.57 Million SEK | -393.192% |
| SpectraCure AB (publ) | 4.39 Million SEK | -862.156% |
| Stille AB | 38.06 Million SEK | -11.139% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 97.744% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | -99.849% |